Overview

Phase 2b Study of ALTO-100 in MDD

Status:
Recruiting

Trial end date:
2024-03-06

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine efficacy differences between ALTO-100 and placebo, used either as monotherapy or adjunctively to an antidepressant, related to patient characteristics.

Phase:

Phase 2

Details

Lead Sponsor:

Alto Neuroscience